Which has preferable valuation and earnings, MDXG or PGEN?

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $355.17M 1.92 $48.58M $0.04 116.75 Precigen $9.68M 285.43 -$250.64M -$1.04 N/A

Is MDXG or PGEN more profitable?

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Precigen -183.98% 423.75% 84.39%

Does the media favor MDXG or PGEN?

In the previous week, Precigen had 8 more articles in the media than MiMedx Group. MarketBeat recorded 16 mentions for Precigen and 8 mentions for MiMedx Group. Precigen's average media sentiment score of 0.68 beat MiMedx Group's score of 0.60 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDXG or NAMS?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 8 mentions for MiMedx Group. NewAmsterdam Pharma's average media sentiment score of 0.90 beat MiMedx Group's score of 0.60 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDXG or CLDX?

In the previous week, Celldex Therapeutics had 23 more articles in the media than MiMedx Group. MarketBeat recorded 31 mentions for Celldex Therapeutics and 8 mentions for MiMedx Group. Celldex Therapeutics' average media sentiment score of 0.87 beat MiMedx Group's score of 0.60 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 15 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MDXG or BEAM?

MiMedx Group has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $355.17M 1.92 $48.58M $0.04 116.75 Beam Therapeutics $156.04M 16.07 -$79.99M -$0.86 N/A

Does the media favor MDXG or BEAM?

In the previous week, MiMedx Group had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.63 beat MiMedx Group's score of 0.60 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDXG or NRIX?

In the previous week, MiMedx Group had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.91 beat MiMedx Group's score of 0.60 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiMedx Group (MDXG) Competitors

$4.67 -0.04 (-0.85%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.66 0.00 (-0.11%)

As of 09/25/2026 07:30 PM Eastern

Compare

MDXG vs. PGEN, NAMS, CLDX, BEAM, and NRIX

Should you buy MiMedx Group stock or one of its competitors? MiMedx Group's main competitors and comparable companies include Precigen (PGEN), NewAmsterdam Pharma (NAMS), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Precigen?

MiMedx Group (NASDAQ:MDXG) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Precigen had 8 more articles in the media than MiMedx Group. MarketBeat recorded 16 mentions for Precigen and 8 mentions for MiMedx Group. Precigen's average media sentiment score of 0.68 beat MiMedx Group's score of 0.60 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	4 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.92	$48.58M	$0.04	116.75
Precigen	$9.68M	285.43	-$250.64M	-$1.04	N/A

MiMedx Group has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Precigen	-183.98%	423.75%	84.39%

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 83.54%. Precigen has a consensus price target of $13.67, indicating a potential upside of 76.34%. Given MiMedx Group's higher possible upside, equities analysts clearly believe MiMedx Group is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

MiMedx Group beats Precigen on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to NewAmsterdam Pharma?

MiMedx Group (NASDAQ:MDXG) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 8 mentions for MiMedx Group. NewAmsterdam Pharma's average media sentiment score of 0.90 beat MiMedx Group's score of 0.60 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

MiMedx Group currently has a consensus target price of $8.57, indicating a potential upside of 83.54%. NewAmsterdam Pharma has a consensus target price of $49.73, indicating a potential upside of 120.23%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

MiMedx Group has a net margin of 1.76% compared to NewAmsterdam Pharma's net margin of -3,644.21%. MiMedx Group's return on equity of 12.09% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

MiMedx Group has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.92	$48.58M	$0.04	116.75
NewAmsterdam Pharma	$22.50M	119.97	-$203.82M	-$2.16	N/A

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats MiMedx Group on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Celldex Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, Celldex Therapeutics had 23 more articles in the media than MiMedx Group. MarketBeat recorded 31 mentions for Celldex Therapeutics and 8 mentions for MiMedx Group. Celldex Therapeutics' average media sentiment score of 0.87 beat MiMedx Group's score of 0.60 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	15 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.2% of MiMedx Group shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MiMedx Group has a net margin of 1.76% compared to Celldex Therapeutics' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Celldex Therapeutics	N/A	-52.35%	-47.61%

MiMedx Group currently has a consensus target price of $8.57, indicating a potential upside of 83.54%. Celldex Therapeutics has a consensus target price of $61.92, indicating a potential upside of 99.11%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

MiMedx Group has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.92	$48.58M	$0.04	116.75
Celldex Therapeutics	$158K	15,457.49	-$258.76M	-$4.35	N/A

Summary

MiMedx Group beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Beam Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 83.54%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 101.90%. Given Beam Therapeutics' higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

MiMedx Group has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.92	$48.58M	$0.04	116.75
Beam Therapeutics	$156.04M	16.07	-$79.99M	-$0.86	N/A

MiMedx Group has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Beam Therapeutics' net margin of -54.75%. MiMedx Group's return on equity of 12.09% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

In the previous week, MiMedx Group had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.63 beat MiMedx Group's score of 0.60 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Nurix Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

MiMedx Group has a net margin of 1.76% compared to Nurix Therapeutics' net margin of -928.44%. MiMedx Group's return on equity of 12.09% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MiMedx Group has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 83.54%. Nurix Therapeutics has a consensus price target of $34.21, indicating a potential upside of 48.69%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

MiMedx Group has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.92	$48.58M	$0.04	116.75
Nurix Therapeutics	$36.77M	64.95	-$264.46M	-$3.45	N/A

In the previous week, MiMedx Group had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.91 beat MiMedx Group's score of 0.60 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$680.70M	$3.94B	$7.33B	$13.18B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	116.78	14.15	275.82	25.78
Price / Sales	1.92	1,300.21	603.86	72.84
Price / Cash	8.43	120.91	79.52	52.89
Price / Book	2.70	15.28	10.44	6.30
Net Income	$48.58M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-2.10%	-2.94%	-1.31%	-0.23%
1 Month Performance	3.55%	-8.80%	-4.61%	-4.16%
1 Year Performance	-32.71%	28.99%	15.01%	4.58%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	2.394 of 5 stars	$4.67 -0.8%	$8.57 +83.5%	-32.7%	$680.70M	$355.17M	116.78	808	News Coverage
PGEN Precigen	3.7916 of 5 stars	$7.88 +2.4%	$14.50 +83.9%	+120.8%	$2.81B	$9.68M	N/A	47	News Coverage Analyst Upgrade Gap Up
NAMS NewAmsterdam Pharma	3.8667 of 5 stars	$23.28 +3.1%	$49.73 +113.7%	-20.8%	$2.79B	$22.50M	N/A	100
CLDX Celldex Therapeutics	2.3322 of 5 stars	$34.23 -9.6%	$59.17 +72.8%	+19.0%	$2.67B	$1.54M	N/A	198	Analyst Forecast Gap Down High Trading Volume
BEAM Beam Therapeutics	2.2513 of 5 stars	$25.86 +2.4%	$49.00 +89.5%	+5.7%	$2.67B	$139.74M	N/A	540

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. PGEN, NAMS, CLDX, BEAM, and NRIX

How does MiMedx Group compare to Precigen?

Summary

How does MiMedx Group compare to NewAmsterdam Pharma?

Summary

How does MiMedx Group compare to Celldex Therapeutics?

Summary

How does MiMedx Group compare to Beam Therapeutics?

Summary

How does MiMedx Group compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. PGEN, NAMS, CLDX, BEAM, and NRIX

How does MiMedx Group compare to Precigen?

Does the media favor MDXG or PGEN?

Which has preferable valuation and earnings, MDXG or PGEN?

Which has more risk & volatility, MDXG or PGEN?

Is MDXG or PGEN more profitable?

Do analysts rate MDXG or PGEN?

Do insiders and institutionals believe in MDXG or PGEN?

Summary

How does MiMedx Group compare to NewAmsterdam Pharma?

Does the media favor MDXG or NAMS?

Which has more risk and volatility, MDXG or NAMS?

Do analysts rate MDXG or NAMS?

Is MDXG or NAMS more profitable?

Which has stronger earnings & valuation, MDXG or NAMS?

Do insiders & institutionals believe in MDXG or NAMS?

Summary

How does MiMedx Group compare to Celldex Therapeutics?

Which has more volatility and risk, MDXG or CLDX?

Does the media prefer MDXG or CLDX?

Do insiders & institutionals hold more shares of MDXG or CLDX?

Is MDXG or CLDX more profitable?

Do analysts prefer MDXG or CLDX?

Which has preferable valuation and earnings, MDXG or CLDX?

Summary

How does MiMedx Group compare to Beam Therapeutics?

Do institutionals & insiders hold more shares of MDXG or BEAM?

Do analysts prefer MDXG or BEAM?

Which has higher earnings & valuation, MDXG or BEAM?

Which has more volatility and risk, MDXG or BEAM?

Is MDXG or BEAM more profitable?

Does the media favor MDXG or BEAM?

Summary

How does MiMedx Group compare to Nurix Therapeutics?

Is MDXG or NRIX more profitable?

Do institutionals and insiders hold more shares of MDXG or NRIX?

Which has more risk and volatility, MDXG or NRIX?

Do analysts recommend MDXG or NRIX?

Which has higher valuation and earnings, MDXG or NRIX?

Does the media favor MDXG or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools